MONTREAL, July 15, 2020 – ExCellThera Inc., a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the appointment of Richard Cherney to its Board of Directors. Mr. Cherney brings over 35 years of experience as trusted advisor to many Canadian corporations including pharmaceutical and biotechnology companies.
“We are delighted to welcome Richard to ExCellThera’s Board of Directors,” said Dr. Guy Sauvageau, CEO and founder of ExCellThera. “We look forward to leveraging his strategic insight and business acumen in biotechnology and life sciences as we embark on the next phase of our growth.”
Richard Cherney is a senior partner at Davies Ward Phillips & Vineberg, has received several distinctions over the last three decades in the areas of mergers & acquisitions and capital markets and is recognized as one of the country’s leading advisors in the life sciences sector. His creativity in the life sciences sector resulted in his recent award as Biotechnology Law Lawyer of the Year by Best Lawyers. Mr. Cherney holds law degrees from McGill University and a Bachelor of Administration degree from Concordia University. Mr. Cherney is also the Chairman of the Montreal General Hospital Foundation.
About ExCellThera Inc.
ExCellThera is a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies, autoimmune and other diseases. ExCellThera’s most advanced technology, ECT-001 Cell Therapy, combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials. excellthera.com